Glasgow, U.K., 4th November 2008 – Research conducted at The University of Strathclyde and Bio-Images Research Ltd., Glasgow, has been successful in achieving quantitative determination of in vivo erosion profiles and in vitro / in vivo correlation for controlled release HPMC matrix tablet formulations using gamma scintigraphy.
Gamma scintigraphy is a well established non-invasive imaging technique with numerous applications in the field of drug delivery. The technique is used to assess the in vivo behaviour of novel formulations, and can also be combined with pharmacokinetics. Information from these studies will assist development decision making, including the development of new formulations as well as re-formulation of existing products, and marketing. Bio-Images have particular expertise in solving concerns with ‘problem’ formulations, such as dose dumping and food effects.
This current study succeeded in characterising the in vivo behaviour of two HPMC matrix tablet formulations in a quantitative manner based on radioactive counts remaining in the tablet core. Correlation with in vitro data was also achieved. The results suggest that differences in erosion profiles between the tablet formulations are linked to the formulation composition and the strength of the HPMC gel layer formed.
Representatives from Bio-Images clinical research team will present these findings at the 2008 American Association of Pharmaceuticals Scientists (AAPS) Annual Meeting in Atlanta, Georgia this month.
Bio-Images are exhibiting at the AAPS show in booth #2360, and will engage the pharmaceutical scientific community with discussions of their gamma scintigraphic services.
Bio-Images Research Ltd. was founded in October 2000 as a spin out company from the University of Strathclyde. Bio-Images undertakes early phase clinical studies in volunteers and patient groups, specialising in gamma scintigraphy. Non-invasive scintigraphic imaging is used to monitor the behaviour of oral, nasal, pulmonary and ophthalmic formulations. Oral site-specific drug absorption studies are performed using the imaGIT® capsule. All studies are fully compliant with ICH-GCP guidelines with all clinical trial supplies manufactured in a GMP facility.
